MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They presently have a $66.00 target price on the stock. Needham & Company LLC's target price would indicate a potential upside of 75.44% from the company's current price.
Other equities research analysts also recently issued research reports about the company. The Goldman Sachs Group decreased their target price on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a report on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. Finally, Royal Bank of Canada assumed coverage on shares of MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $67.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $81.67.
View Our Latest Stock Analysis on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Price Performance
MoonLake Immunotherapeutics stock traded down $0.04 during mid-day trading on Tuesday, reaching $37.62. 351,510 shares of the company traded hands, compared to its average volume of 356,351. The firm's fifty day moving average is $38.40 and its two-hundred day moving average is $44.71. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of -29.16 and a beta of 1.31. MoonLake Immunotherapeutics has a fifty-two week low of $31.42 and a fifty-two week high of $58.26.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same period last year, the company earned ($0.22) earnings per share. As a group, equities research analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.
Institutional Investors Weigh In On MoonLake Immunotherapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC boosted its holdings in MoonLake Immunotherapeutics by 28.1% during the fourth quarter. FMR LLC now owns 6,341,391 shares of the company's stock worth $343,386,000 after buying an additional 1,391,167 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of MoonLake Immunotherapeutics by 12.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company's stock worth $181,059,000 after acquiring an additional 363,394 shares during the period. Paradigm Biocapital Advisors LP boosted its stake in shares of MoonLake Immunotherapeutics by 90.3% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company's stock worth $95,965,000 after acquiring an additional 840,731 shares in the last quarter. Westfield Capital Management Co. LP grew its position in shares of MoonLake Immunotherapeutics by 9.4% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,434,770 shares of the company's stock valued at $56,056,000 after acquiring an additional 123,151 shares during the period. Finally, Federated Hermes Inc. increased its stake in shares of MoonLake Immunotherapeutics by 13.2% in the 4th quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company's stock valued at $69,315,000 after purchasing an additional 149,724 shares in the last quarter. Institutional investors and hedge funds own 93.85% of the company's stock.
About MoonLake Immunotherapeutics
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Read More
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
